Can Artificial Intelligence Help With Market Access?
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.
You may also be interested in...
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.